Achilles Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

07/01/2020

Stevenage, UK 7 January 2020 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, 14 January 2020 at 8:30 a.m. Pacific Time. The event will be held in San Francisco at the Westin St. Francis.

– Ends –

About Achilles Therapeutics
Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.
Achilles was founded in 2016 by lead investor Syncona Ltd and in September 2019 the Company raised £100M in an oversubscribed Series B financing led by RA Capital, cornerstoned by Syncona and joined by new investors including Forbion, Invus, Perceptive Advisors and Redmile Group. For further information please visit the Company’s website at: www.achillestx.com

Further information:

Achilles Therapeutics
Dr Iraj Ali – Chief Executive Officer
+44 (0)1438 906 906
media@achillestx.com

Julia Wilson – Head of Communications
+44 (0)7818 430877
j.wilson@achillestx.com

Consilium Strategic Communications
Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner
Tel: +44 (0) 203 709 5000
Email: achillestx@consilium-comms.com

US Investor Relations – Solebury Trout
Lee Stern
+1 646-378-2922
lstern@troutgroup.com

AchillesLatest News

Achilles Therapeutics appoints Daniel Hood as Chief Legal Officer

07/07/2020

Stevenage, UK 7 July 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announces that...

Read More +

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

23/06/2020

Stevenage, UK 23 June 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that...

Read More +

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens

29/05/2020

Stevenage, UK 29 May 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that...

Read More +